Clinical Trials and Research

Login or register to access the content restricted to healthcare professionals only

ADVANCED CLINICAL TRIAL PIPELINE

CLINICAL TRIAL	EXTRACT	BACKGROUND	CURRENT STATUS	COMMENT
Phase II Insomnia Study	Bod Bio Absorb	Using a novel CBD to treat insomnia	IN PROGRESS	The study will provide data that will be key in supporting a TGA registration to allow the product to be sold over the counter in Australian pharmacies.
Project Skin	Novel Protein	Evaluating the efficacy of a novel protein for the inhibition of free radical damage on skin	IN PROGRESS	At completion, Bod will own a unique and novel delivery format of an anti-aging agent for topical use
Project Chang’e	Bod ECS317 & Bod ECS100	Evaluating the combination of different cannabinoids and probiotics targeting stress, anxiety and inflammation in animals	IN PROGRESS	This data will support future product launches utilizing the combination of CBG and CBD.
Emerald Study (Phase II)	Bod ECS315	The use of CBD in slowing progression of Motor Neuron Disease	IN PROGRESS	Collaboration with Gold Coast University Hospital
Phase I CBN Insomnia Study	Bod Es310	Using CBN to treat primary insomnia	IN PROGRESS	Collaboration with University of Sydney & The Woolcock Institute of Medical Research
Phase 1 PK Study	Bod Bio Absorb	Pharmacokinetics, safety and tolerability of novel CBD compound	COMPLETED	The study data will support regulatory registrations and other commercial opportunities.
Long Covid Study	Bod ECS315	Evaluating the safety and tolerability of CBD for symptoms associated with Long Covid	COMPLETED	This study provides a unique opportunity to further research into the potential to alleviate symptoms of Long Covid using CBD
Phase I PK Study	Bod ECS315	Pharmacokinetics safety and tolerability of CBD extract	COMPLETED	This work optimised the design of our Phase II Insomnia Study
Toxicology	Bod ECS315	Safety evaluation of ECS315 For Novel br Food Registration	COMPLETED	Bod is one of six companies globally to have secured a validated Novel Food Application. This is mandatory for CBD to be sold in the UK and EU.
BODOLOS Observational Study	Bod ECS315 & Bod ECS100	Real world evidence on doctors CBD prescribing habits	COMPLETED	The study provided key insights into dosing decisions and the design of our Phase II Insomnia Study.
CBG Pilot Study	Bod ECS317	Evaluation of the efficacy of a novel	COMPLETED	The study investigated the effect of CBG on symptoms associated with fibromyalgia, inflammatory bowel disease and anxiety.